Can Fluid Biomarkers Safely Guide MS DMT De‑escalation?

Researchers are exploring whether fluid biomarkers could offer a safer way to gradually reduce disease-modifying therapies (DMTs) in multiple sclerosis (MS) patients, potentially avoiding unnecessary treatment while monitoring disease activity. This approach could reduce side effects and improve patient quality of life, making it a significant advancement in MS management. By utilizing biomarkers in cerebrospinal fluid, doctors aim to tailor treatments more precisely, reflecting the current state of MS activity and ensuring patients receive the most effective care without overtreatment.